Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice.
Frontiers in cardiovascular medicine（2022）
摘要
Empagliflozin inhibited CMD and reduced cardiac pericyte loss in diabetic mice.
更多查看译文
关键词
coronary microvascular dysfunction,diabetes,empagliflozin,pericytes,sodium-glucose cotransporter 2 inhibitors
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要